查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1559915

全球腮腺炎疫苗市場：趨勢、預測與競爭分析（~2030）

Mumps Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年，全球腮腺炎疫苗市場規模將達到 11 億美元，2024 年至 2030 年複合年成長率為 8.6%。市場的主要促進因素是腮腺炎感染疾病的高盛行率和盛行率、對高效、安全的腮腺炎疫苗的需求不斷成長以及政府對腮腺炎疫苗接種計劃的支持不斷增加。全球腮腺炎疫苗市場的未來可能包括小兒科診所、醫院和非政府組織市場的機會。

預計組合將在預測期內實現最高成長，因為它具有便利性和成本效益等優勢。

在這個市場中，由於兒童廣泛使用腮腺炎疫苗，小兒科診所將繼續成為最大的市場區隔。

預計北美在預測期內將經歷最高的成長。

腮腺炎疫苗市場新動向

腮腺炎疫苗市場的新趨勢反映了疫苗技術的變化、保險覆蓋力度的增加以及人們對腮腺炎預防意識的增強。

  • 技術進步：配方技術和輸送系統的創新有助於提高腮腺炎疫苗的功效和安全性。
  • 提高疫苗接種覆蓋率：透過公共衛生宣傳活動和納入常規免疫計畫來提高疫苗接種覆蓋率，正在提高世界各地腮腺炎預防的有效性。
  • 加強劑量：加強劑量對於維持長期免疫力至關重要，並有助於在疫苗保護作用下降時中和腮腺炎的爆發。
  • 全球衛生措施：近年來，與疫苗取得和疫苗接種率相關的全球衛生措施有所增加，特別是在低收入和中等收入國家。
  • 解決疫苗抗藥性：將加強公眾教育和溝通，以解決疫苗猶豫問題並提高接種率。

這將成為腮腺炎疫苗市場變化的關鍵驅動力，疫苗功效隨著覆蓋範圍和整體公共衛生反應的增加而提高。

腮腺炎疫苗市場近期趨勢

腮腺炎疫苗市場的開拓重點在於改善疫苗、改變政策、擴大疫苗接種覆蓋率。

  • 開發改良的疫苗配方 為疫苗開發的新配方旨在提高安全性和有效性，並提高對流行性腮腺炎感染併發症的保護。
  • 加強劑的新優先事項：在時間表中添加加強劑也將有助於減少諸如人群免疫力減弱和最近流行性腮腺炎死灰復燃等問題。
  • 擴大免疫規劃：將腮腺炎疫苗納入常規免疫規劃的努力正在加強努力，特別是在貧困地區和低收入國家。
  • 改善疫苗監測：改善監測和監測系統可以有效追蹤腮腺炎病例和疫苗有效性，為實證公共衛生應對措施提供資訊。
  • 全球衛生：全球衛生合作和舉措正在將重點轉向確保疫苗的取得和覆蓋率，特別是在世界上覆蓋率仍然較低的地區。

這將提高腮腺炎疫苗接種計劃的效率和覆蓋範圍，並改善全球感染控制。

腮腺炎疫苗市場的策略性成長機會

腮腺炎疫苗市場的策略性成長機會包括疫苗需求的增加、免疫計畫的擴大和技術進步。

  • 常規免疫計畫：將流行性腮腺炎疫苗納入常規免疫計畫將提高感染率和幼兒期保護，創造成長機會。
  • 加強計畫：進一步實施和擴大加強計畫可以解決免疫力下降的問題，並改善對流行性腮腺炎的長期保護。
  • 公共衛生宣傳活動：擴大公共衛生宣傳活動以意識提升並克服對疫苗接種的猶豫不決，有可能提高疫苗接種覆蓋率並減少感染疾病的發生率。
  • 全球衛生夥伴關係：與全球衛生夥伴的合作將有助於擴大低收入和中等收入國家疫苗取得和分配的範圍和公平性。預計這將擴大市場並進一步改善全球健康。
  • 創新：對新疫苗技術和輸送系統的投資為提高疫苗功效和安全性提供了新的可能性，從而提高了疫苗的市場接受度。

所有這些策略機會都將改善腮腺炎疫苗的取得、功效和覆蓋範圍，推動市場成長。

腮腺炎疫苗市場的促進因素與挑戰

各種技術、經濟和監管因素正在影響腮腺炎疫苗市場，其中包括促進因素和挑戰因素。

推動腮腺炎疫苗市場的因素包括：

1. 技術進步：創新疫苗和輸送系統的開發正在提高疫苗安全性和有效性的標準，並推動市場發展。

2. 提高疫苗接種意識：提高腮腺炎疫苗接種意識導致疫苗接種率提高。

3. 政府政策：有利的政府政策和疫苗接種計畫的撥款正在促進疫苗的取得並刺激市場的進一步成長。

4. 全球健康舉措：國際夥伴關係和衛生計劃正在幫助改善疫苗的供應和獲取，特別是在資源匱乏的環境中。

腮腺炎疫苗市場的挑戰包括：

1. 疫苗供應挑戰：供應鏈中斷會嚴重影響疫苗的供應和獲取，進而影響疫苗接種計劃，最終影響市場穩定。

2. 疫苗分發挑戰：與疫苗分發相關的後勤挑戰，特別是在偏遠地區，是有效免疫和市場成長的主要障礙。

3. 確保法規遵循：法規要求的複雜性可能很困難，並且會影響市場准入和產品可用性。

這些市場促進因素和挑戰將透過對疫苗開發、疫苗接種率和整體公共衛生的影響來影響腮腺炎疫苗市場的形成。

腮腺炎疫苗按市場

這項研究按產品類型、年齡層、最終用途和地區對全球腮腺炎疫苗進行了預測。

各國腮腺炎疫苗市場前景

疫苗技術的進步、當地衛生政策和不斷興起的全球衛生措施正在推動腮腺炎疫苗市場的近期發展。

  • 美國：為了應對該國最近爆發的疫情，該國在疫苗配方和加強劑量的使用方面取得了進展。我們也正在改進監測和疫苗宣傳活動，以阻止疫苗接種覆蓋率下降，從而阻止腮腺炎病毒感染疾病的死灰復燃。
  • 中國：擴大腮腺炎免疫規劃，納入一般免疫規劃。人們也非常關注提高農村地區的疫苗接種率並透過公共教育減少疫苗猶豫。
  • 德國：制定新的疫苗接種指南並改善疫苗的獲取，制定更廣泛的腮腺炎控制策略。透過公共衛生宣傳活動確保充足的疫苗接種也是該國面臨的關鍵挑戰。
  • 印度：隨著印度希望將疫苗接種活動覆蓋到最貧困地區的更多地區，該市場正在持續成長。正在繼續努力將腮腺炎疫苗納入國家免疫規劃，並改善疫苗運輸的物流。
  • 日本：日本修訂了疫苗接種指南，建議加強接種腮腺炎疫苗。日本也正在加強其疫苗監測系統，以便更好地監測腮腺炎發生率和疫苗有效性。

常問問題

Q.1 腮腺炎疫苗的市場規模有多大？

A1. 預計到 2030 年，全球腮腺炎疫苗市場將達到 11 億美元。

Q.2 腮腺炎疫苗市場的成長預測如何？

A2. 預計 2024 年至 2030 年全球腮腺炎疫苗市場將以 8.6% 的複合年成長率成長。

Q.3 影響腮腺炎疫苗市場成長的關鍵促進因素有哪些？

A3. 該市場的主要促進因素是腮腺炎感染的高盛行率和發病率、對高效和安全的腮腺炎疫苗的需求不斷成長以及政府對腮腺炎疫苗接種計劃的支持不斷增加。

Q4.市場的主要細分市場是：

A4. 腮腺炎疫苗市場前景廣闊，小兒科診所、醫院和非政府組織市場都有機會。

Q5.市場的主要企業是：

A5.主要企業如下：

  • MedImmune
  • Johnson & Johnson
  • Merck
  • Sanofi
  • Serum Institute of India
  • Bavarian Nordic
  • Astellas Pharma India
  • CSL
  • Emergent BioSolutions
  • GlaxoSmithKline

Q6.未來最大的細分市場是什麼？

A6.我們預計，由於其便利性和成本效益等優勢，組合將在預測期內達到最高成長。

Q7. 未來五年預計哪些地區的市場成長最大？

A7. 預計北美地區在預測期內將出現最高成長。

Q8. 可以客製化報告嗎？

A8. 是的，我們提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章全球腮腺炎疫苗市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球腮腺炎疫苗市場趨勢（2018-2023）與預測（2024-2030）
  • 全球腮腺炎疫苗市場：依產品類型
    • 單價
    • 組合
    • 二價
    • 三價
    • 其他
  • 全球腮腺炎疫苗市場：依年齡層分類
    • 兒科的
    • 成人
  • 全球腮腺炎疫苗市場：依最終用途分類
    • 小兒科診所
    • 醫院
    • NGO
    • 其他

第 4 章 2018-2030 年按地區分類的市場趨勢與預測分析

  • 全球腮腺炎疫苗市場：依地區
  • 北美腮腺炎疫苗市場
  • 歐洲腮腺炎疫苗市場
  • 亞太地區流行性腮腺炎疫苗市場
  • 其他地區腮腺炎疫苗市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 依產品類型
    • 按年齡層別
    • 按最終用途
    • 按地區
  • 全球腮腺炎疫苗市場新趨勢
  • 戰略分析
    • 新產品開發
    • 全球腮腺炎疫苗市場產能擴張
    • 全球腮腺炎疫苗市場的併購和合資企業
    • 認證和許可

第7章主要企業概況

  • MedImmune
  • Johnson & Johnson
  • Merck
  • Sanofi
  • Serum Institute of India
  • Bavarian Nordic
  • Astellas Pharma India
  • CSL
  • Emergent BioSolutions
  • GlaxoSmithKline
簡介目錄

Mumps Vaccine Trends and Forecast

The future of the global mumps vaccine market looks promising with opportunities in the pediatric clinic, hospital, and NGO markets. The global mumps vaccine market is expected to reach an estimated $1.1 billion by 2030 with a CAGR of 8.6% from 2024 to 2030. The major drivers for this market are high prevalence and morbidity of mumps infection, growing demand for efficient and safe mumps vaccines, and rising government support for mumps vaccination programs.

Lucintel forecasts that combinational is expected to witness highest growth over the forecast period due to its advantages like convenience and cost-effectiveness.

Within this market, pediatric clinic will remain the largest segment due to significant application of mumps vaccine among children.

North America is expected to witness highest growth over the forecast period.

Emerging Trends in the Mumps Vaccine Market

Developing trends in the mumps vaccine market are testament to changing vaccine technology, increasing coverage efforts, and growing awareness about the prevention of mumps.

  • Technological Advancement: Innovations in the technology of formulation and delivery systems contribute to enhancing the efficacy and safety profiles of the vaccines against mumps.
  • Increased Vaccination Coverage: Increased vaccination coverage through public health campaigns and integration into routine immunization programs has been expanding protection against mumps across the globe.
  • Booster Doses: Increasingly, there is emphasis on booster doses, which are very crucial for long-term immunity and help neutralize mumps outbreaks associated with waning vaccine protection.
  • Global Health Initiatives: Global health initiatives of collaboration on access to and coverage of vaccines have increased in recent years, particularly for low- and middle-income countries.
  • Addressing Vaccine Hesitancy: Public education and communication are enhanced to address vaccine hesitancy and improve vaccination rates.

This in turn would act as a key driver of change within the mumps vaccine market, where the efficacy of the vaccines would increase, along with coverage and the overall public health response.

Recent Developments in the Mumps Vaccine Market

The development in the mumps vaccine market is focused on improving vaccines, policy changes, and the expansion of vaccination.

  • Development of Improved Vaccine Formulations: New formulations developed for vaccines are intended to enhance their safety and efficacy profiles, enabling their improved protective function against complications due to mumps infections.
  • Booster Doses a New Priority: Booster doses added to the schedules will also keep such issues at bay as waning immunity of populations and recent resurgences of mumps outbreaks.
  • Expansion of Immunization Programs: There is increased effort toward integrating the mumps vaccine into routine immunization programs, especially in most deprived areas and low-income countries.
  • Improved Vaccine Surveillance: With this, the improvement in monitoring and surveillance systems enables the effective tracking of cases and the effectiveness of vaccines against the disease to inform evidence-based public health responses.
  • Global Health: Global health collaborations and initiatives have shifted focus toward ensuring access to and coverage of vaccines, particularly in those areas of the world where vaccination rates remain low.

Accordingly, the improvements described enhance the efficiency and coverage of mumps vaccination programs, thus improving global control of the infection.

Strategic Growth Opportunities for Mumps Vaccine Market

The strategic growth opportunities in the mumps vaccine market include an increasing demand for vaccines, expanded immunization programs, and technological advancements.

  • Routine Immunization Programs: The expanding mumps vaccine into routine immunization programs creates growth opportunities through increased coverage and protection from early childhood onwards.
  • Booster Dose Programs: Increased implementation and expansion of booster dose programs can help to address issues of waning immunity and improve long-term protection against mumps.
  • Public Health Campaigns: Expanding the sphere of public health campaigns toward creating awareness and overcoming vaccine hesitancy will present potential ways to increase vaccination rates, hence lowering the rate of infectious diseases.
  • Global Health Partnerships: Collaboration with global health partners may be helpful in extending the reach and equity of vaccine access and distribution in low- and middle-income countries. This will likely ensure market growth and further global health improvement.
  • Technological Innovations: Investment in new vaccine technologies and delivery systems offers new possibilities to improve vaccine efficacy and safety, leading to wider market acceptance of the vaccines.

All these strategic opportunities enhance access, efficacy, and coverage for mumps vaccines, thus driving market growth.

Mumps Vaccine Market Driver and Challenges

Various technological, economic, and regulatory factors are affecting the mumps vaccines market, which includes both driving and challenging factors.

The factors responsible for driving the mumps vaccine market include:

1. Technological Advancement: The development of new innovative vaccines and delivery systems raises the bar on vaccine safety and efficacy, thereby driving the market.

2. Increased Vaccination Awareness: Increasing awareness toward vaccination against mumps diseases is leading to a rise in vaccination rates.

3. Government Policies: Favorable government policies and allocations toward vaccination programs spur the market to grow further, easing access to the vaccines.

4. Global Health Initiative: International collaborations and health initiatives help improve vaccine availability and access, particularly within resource-poor settings

Challenges in the mumps vaccine market are:

1. Vaccine Supply Challenges: Disruptions in supply chains seriously affect the availability and access to vaccines, thus impacting vaccination programs and ultimately market stability.

2. Vaccine Distribution Challenges: Logistical challenges related to vaccine distribution, particularly in far-flung areas, act as a major hindrance toward effective immunization and market growth.

3. Ensuring Regulatory Compliance: The complexity of regulatory requirements is challenging and may impact market entry and product availability.

These drivers and challenges influence the shaping of the mumps vaccine market by their effect on vaccine development, coverage, and overall public health outcomes.

List of Mumps Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies mumps vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the mumps vaccine companies profiled in this report include-

  • MedImmune
  • Johnson & Johnson
  • Merck
  • Sanofi
  • Serum Institute of India
  • Bavarian Nordic
  • Astellas Pharma India
  • CSL
  • Emergent BioSolutions
  • GlaxoSmithKline

Mumps Vaccine by Segment

The study includes a forecast for the global mumps vaccine by product type, age group, end use, and region.

Mumps Vaccine Market by Product Type [Analysis by Value from 2018 to 2030]:

  • Monovalent
  • Combinational
  • Divalent
  • Trivalent
  • Others

Mumps Vaccine Market by Age Group [Analysis by Value from 2018 to 2030]:

  • Pediatric
  • Adult

Mumps Vaccine Market by End Use [Analysis by Value from 2018 to 2030]:

  • Pediatric Clinic
  • Hospitals
  • NGOs
  • Others

Mumps Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Mumps Vaccine Market

The advancement of vaccine technology, regional health policies, and growing global health initiatives are driving development in the recent mumps vaccine market.

  • United States: The country has recorded developments in relation to advancements in the formulation of vaccines and the uptake of booster doses as a response to the outbreaks recorded in the country lately. It is also putting in place an improved monitoring and vaccination campaign to try and stem the decline in vaccine coverage that contributes to the resurgence of the mumps virus infection.
  • China expanded the mumps vaccination program by incorporating it into the general immunization program. Much attention is also paid to the improvement of vaccine coverage in rural areas and vaccination hesitancy through public education.
  • Germany designed new vaccination guidelines and increased accessibility to vaccines within the broader strategy to control mumps. Another significant task for this country is to ensure adequate vaccinations by promoting public health campaigns.
  • India: The mumps vaccine market is growing continuously as India tries to cover more and more ground in terms of vaccination outreach in its most under-resourced areas. There are continuing activities aimed at the integration of the mumps vaccine into the national immunization schedule, while the improvement of logistics regarding vaccine delivery is also being pursued.
  • Japan: Japan has revised its guidelines for vaccination by recommending booster doses of the mumps vaccine. Japan is also strengthening surveillance systems for vaccines in order to monitor better the incidence of the disease and effective performance of vaccines.

Features of the Global Mumps Vaccine Market

Market Size Estimates: Mumps vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Mumps vaccine market size by product type, age group, end use, and region in terms of value ($B).

Regional Analysis: Mumps vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, age groups, end uses, and regions for the mumps vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the mumps vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the mumps vaccine market size?

Answer: The global mumps vaccine market is expected to reach an estimated $1.1 billion by 2030.

Q.2 What is the growth forecast for mumps vaccine market?

Answer: The global mumps vaccine market is expected to grow with a CAGR of 8.6% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the mumps vaccine market?

Answer: The major drivers for this market are high prevalence and morbidity of mumps infection, growing demand for efficient and safe mumps vaccines, and rising government support for mumps vaccination programs.

Q4. What are the major segments for mumps vaccine market?

Answer: The future of the mumps vaccine market looks promising with opportunities in the pediatric clinic, hospital, and NGO markets.

Q5. Who are the key mumps vaccine market companies?

Answer: Some of the key mumps vaccine companies are as follows:

  • MedImmune
  • Johnson & Johnson
  • Merck
  • Sanofi
  • Serum Institute of India
  • Bavarian Nordic
  • Astellas Pharma India
  • CSL
  • Emergent BioSolutions
  • GlaxoSmithKline

Q6. Which mumps vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that combinational is expected to witness highest growth over the forecast period due to its advantages like convenience and cost-effectiveness.

Q7. In mumps vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the mumps vaccine market by product type (monovalent, combinational, divalent, trivalent, and others), age group (pediatric and adult), end use (pediatric clinic, hospitals, NGOs, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
  • Market Report

Table of Contents

1. Executive Summary

2. Global Mumps Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Mumps Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Mumps Vaccine Market by Product Type
    • 3.3.1: Monovalent
    • 3.3.2: Combinational
    • 3.3.3: Divalent
    • 3.3.4: Trivalent
    • 3.3.5: Others
  • 3.4: Global Mumps Vaccine Market by Age Group
    • 3.4.1: Pediatric
    • 3.4.2: Adult
  • 3.5: Global Mumps Vaccine Market by End Use
    • 3.5.1: Pediatric Clinic
    • 3.5.2: Hospitals
    • 3.5.3: NGOs
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Mumps Vaccine Market by Region
  • 4.2: North American Mumps Vaccine Market
    • 4.2.1: North American Mumps Vaccine Market by Product Type: Monovalent, Combinational, Divalent, Trivalent, and Others
    • 4.2.2: North American Mumps Vaccine Market by End Use: Pediatric Clinic, Hospitals, NGOs, and Others
  • 4.3: European Mumps Vaccine Market
    • 4.3.1: European Mumps Vaccine Market by Product Type: Monovalent, Combinational, Divalent, Trivalent, and Others
    • 4.3.2: European Mumps Vaccine Market by End Use: Pediatric Clinic, Hospitals, NGOs, and Others
  • 4.4: APAC Mumps Vaccine Market
    • 4.4.1: APAC Mumps Vaccine Market by Product Type: Monovalent, Combinational, Divalent, Trivalent, and Others
    • 4.4.2: APAC Mumps Vaccine Market by End Use: Pediatric Clinic, Hospitals, NGOs, and Others
  • 4.5: ROW Mumps Vaccine Market
    • 4.5.1: ROW Mumps Vaccine Market by Product Type: Monovalent, Combinational, Divalent, Trivalent, and Others
    • 4.5.2: ROW Mumps Vaccine Market by End Use: Pediatric Clinic, Hospitals, NGOs, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Mumps Vaccine Market by Product Type
    • 6.1.2: Growth Opportunities for the Global Mumps Vaccine Market by Age Group
    • 6.1.3: Growth Opportunities for the Global Mumps Vaccine Market by End Use
    • 6.1.4: Growth Opportunities for the Global Mumps Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Mumps Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Mumps Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Mumps Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: MedImmune
  • 7.2: Johnson & Johnson
  • 7.3: Merck
  • 7.4: Sanofi
  • 7.5: Serum Institute of India
  • 7.6: Bavarian Nordic
  • 7.7: Astellas Pharma India
  • 7.8: CSL
  • 7.9: Emergent BioSolutions
  • 7.10: GlaxoSmithKline